Affiliated Treatment Facilities
01. Doctor Overview
Doctor Overview
With nearly three decades of medical experience, Dr. John A. Chabot is an expert in the surgical treatment of pancreatic cancer and peritoneal mesothelioma. Upon completion of his residency in 1991, Dr. Chabot signed on as surgical chief of the thyroid clinic at NewYork-Presbyterian and assistant professor of surgery at Columbia University. He has remained at the hospital, in increasingly senior positions, ever since. Throughout the years, Dr. Chabot has remained satisfied and challenged at NewYork-Presbyterian because of the hospital’s depth of expertise and its culture of innovation. Dr. Chabot has researched and published numerous articles and abstracts on the surgical treatment of pancreatic, parathyroid, thyroid and liver disease, as well as peritoneal mesothelioma.
02. Fast Facts
Doctor Fast Facts
Main Specialty: General Surgery
Other Interests & Specialties: Cancer care, pancreatic disease, cysts, surgery, tumor and cancer, mesothelioma, thyroid cancer, liver cancer, hepatobiliary pancreas disease, pancreas and biliary tract surgery, gastrointestinal cancer, liver resection surgery, sarcoma, pancreatitis laparoscopic cholecystectomy and jaundice.
Certifications, Awards & Accolades: American Board of Surgery Certification in Surgery, named one of New York Magazine’s Top Doctors, Jerry Gliklich Practitioner of the Year Award, Teaching Award in Surgery for Excellence in Teaching and Mentoring
Education & Experience:
- Medical Degree from Dartmouth Medical School
- Internship at Columbia Presbyterian Medical Center
- Residency at Columbia Presbyterian Medical Center
- Fellowship at Dartmouth-Hitchcock Medical Center
03. Publications
Publications
Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology. April 2016; 68(5): 729-737. doi: 10.1111/his.12807
Quantitative X-ray Computed Tomography Peritoneography in Malignant Peritoneal Mesothelioma Patients Receiving Intraperitoneal Chemotherapy. Annals of Surgical Oncology. December 2013: 20(3): 553-559. doi: 10.1245/s10434-013-2976-8
Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. European Journal of Surgical Oncology. October 2010; 36 (10): 997-1003. doi: 10.1016/j.ejso.2010.07.001
Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma. American Journal of Clinical Oncology. February 2008; 31(1): 49-54. doi: 10.1097/COC.0b013e3180684181
P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma. Clinical Cancer Research. May 2005; 11(9): 3303-3308. doi: 10.1158/1078-0432.CCR-04-1884
Treatment of Primary Peritoneal Mesothelioma by Hyperthemic Intraperitoneal Chemotherapy. Perfusion. March 1999;14(2):141-5. doi: 10.1177/026765919901400208
